A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.

Abstract

Multicentric Castleman's disease (MCD) is a rare systemic lymphoproliferative disorder with too few patient series reported in the literature to have a clear idea about the etiology, outcome and the best treatment available. Systemic reactive amyloidosis is a very rare complication of MCD and its presence worsens the prognosis. We report a case of a 28-year-old patient with plasma-cell type, human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative MCD who responded to treatment with chemotherapy and the anti-CD20 monoclonal antibody, rituximab. Anti-CD20 therapy could be an interesting adjunctive treatment in MCD.

• Authors: Dany Gholam, Jean-Marie Vantelon, Ahmad Al-Jijakli, Jean-Henri Bourhis
• Journal: Annals of hematology (Ann Hematol) Vol. 82 Issue 12 Pg. 766-8 (Dec 2003) ISSN: 1432-0584 [Electronic] Germany
• PMID: 12898190 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Rituximab

Topics

• Adult
• Amyloidosis (complications, drug therapy, pathology)
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Castleman Disease (complications, drug therapy)
• Female
• Humans
• Multiple Organ Failure (drug therapy)
• Rituximab